Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 27:10:203.
doi: 10.3389/fonc.2020.00203. eCollection 2020.

Prostate Fiducial Marker Placement in Patients on Anticoagulation: Feasibility Prior to Prostate SBRT

Michelle Iocolano  1   2 , Seth Blacksburg  1 , Todd Carpenter  1 , Michael Repka  1 , Susan Carbone  1 , Gizem Demircioglu  1 , Maryann Miccio  1 , Aaron Katz  3 , Jonathan Haas  1
Affiliations

Prostate Fiducial Marker Placement in Patients on Anticoagulation: Feasibility Prior to Prostate SBRT

Michelle Iocolano et al. Front Oncol. .

Abstract

Background and Purpose: Fiducial marker placement is required in patients undergoing robotic-based Stereotactic Body Radiotherapy (SBRT) or image-guided radiation therapy (IGRT) for prostate cancer. Many patients take antiplatelet or anticoagulant medication due to other medical comorbidities. They are often required to temporarily discontinue these medications prior to invasive medical procedures as they are prone to bleed. Some patients are unable to discontinue therapy due to an elevated risk of thromboembolic events. The purpose of this study is to report this institution's experience placing fiducial markers in prostate cancer patients who are on chronic antiplatelet or anticoagulant medication. Materials and Methods: From August 2015-March 2019 57 patients on chronic antiplatelet or anticoagulation therapy who were not cleared to stop these medications underwent transrectal ultrasound guided (TRUS) fiducial marker placement for SBRT/IGRT. All patients were monitored by a registered nurse during the procedure for prolonged bleeding that required staff to hold pressure to the area with a 4 × 4 gauze until it resolved. All patients were also called the following day to assess for ongoing bleeding events. Treatment planning CT scan confirmed the ideal geometry of the marker placement. Results: All 57 patients on antiplatelet or anticoagulant medication who underwent fiducial marker placement were discharged home the same day of the procedure. Four patients experienced persistent bleeding that required a nurse to hold prolonged pressure to the area. No patient experienced significant bleeding the following day or any untoward cardiovascular event. Conclusions: This series suggests the use of antiplatelet or anticoagulant medication is not an absolute contraindication to fiducial marker placement in patients undergoing SBRT or IGRT for prostate cancer. These patients should be closely monitored after the procedure for bleeding complications. Practitioners may consider the patient's medical comorbidities, risk factors for thromboembolism, and overall functional status as there is no standardized protocol for discontinuing anticoagulant or antiplatelet therapy for fiducial marker placement.

Keywords: SBRT; anticoagulants; fiducial markers; image-guided; prostate cancer; radiotherapy.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. (2019) 69:7–34. 10.3322/caac.21551 - DOI - PubMed
    1. Boyer MJ, Papagikos MA, Kiteley R, Vujaskovic Z, Wu J, Robert Lee W. Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer. Radiat Oncol. (2017) 12:14. 10.1186/s13014-016-0758-8 - DOI - PMC - PubMed
    1. Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. . Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. (2019) 394:385–95. 10.1016/S0140-6736(19)31131-6 - DOI - PubMed
    1. Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, et al. . Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. (2019) 2:e188006. 10.1001/jamanetworkopen.2018.8006 - DOI - PMC - PubMed
    1. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. . Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B):acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. (2019) 20:1531–43. 10.1016/S1470-2045(19)30569-8 - DOI - PMC - PubMed

LinkOut - more resources